Boothbay Fund Management’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.13M | Sell |
108,969
-31,004
| -22% | -$892K | 0.06% | 284 |
|
|
2025
Q1 | $4.69M | Buy |
139,973
+2,221
| +2% | +$74.5K | 0.12% | 173 |
|
|
2024
Q4 | $7.04M | Buy |
137,752
+28,327
| +26% | +$1.45M | 0.17% | 138 |
|
|
2024
Q3 | $5.59M | Sell |
109,425
-41,499
| -27% | -$2.12M | 0.13% | 177 |
|
|
2024
Q2 | $6.76M | Sell |
150,924
-11,602
| -7% | -$520K | 0.16% | 119 |
|
|
2024
Q1 | $7.61M | Buy |
162,526
+17,615
| +12% | +$825K | 0.15% | 95 |
|
|
2023
Q4 | $5.16M | Sell |
144,911
-22,327
| -13% | -$794K | 0.13% | 149 |
|
|
2023
Q3 | $4.97M | Buy |
167,238
+70,433
| +73% | +$2.09M | 0.12% | 173 |
|
|
2023
Q2 | $1.74M | Buy |
+96,805
| New | +$1.74M | 0.04% | 489 |
|
|
2020
Q3 | – | Sell |
-11,855
| Closed | -$208K | – | 948 |
|
|
2020
Q2 | $208K | Buy |
+11,855
| New | +$208K | 0.01% | 666 |
|